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1. Introduction 
Colorectal cancer (CRC) remains one of the most deadly diseases in the western world, and 
starts to become a concern in developed countries (Labianca et al., 2010). However, 
significant steps have been made recently in CRC therapy. Until the 80’s, 5-fluorouracil (5-
FU) was the only available drug to treat patients, with limited efficacy. Today, 4 cytotoxic 
agents (5-FU associated with folinic acid, capecitabine, oxaliplatin, irinotecan) and three 
monoclonal antibodies (cetuximab, panitumumab, bevacizumab) are available, mostly as 
part of combinations (Koutras et al., 2011). In particular, the rise of targeted therapies in 
digestive oncology has fueled a new hope by significantly stretching the therapeutic options 
available so far. Despite these improvements, treatment of metastatic CRC (mCRC) remains 
a challenging task, and it is acknowledged now that although improving response rates, the 
introduction of the latest targeted therapies only marginally impacts on either progression 
free survival (PFS) or overall survival (OS) of mCRC patients. Because of the cost of these 
new therapies, identifying biomarkers likely to sort patients on their ability to benefit or not, 
from these new drugs is paradigmatic of the current trend to move towards a more 
personalized medicine in oncology. Because genetic variability is one of the main factor 
regulating efficacy and toxicity of most anticancer agents, addressing the issues of 
pharmacogenomics and pharmacogenetics (PGx) in CRC patient becomes critical, far 
beyond the only use of costly targeted therapies. Although often used interchangeably, the 
term “pharmacogenetics” refers historically to inherited changes in genes coding for drug 
metabolizing enzymes or membrane transporters, thus impacting on the pharmacokinetic 
(PK) profile and exposure levels eventually, whereas “pharmacogenomics” is a broader 
definition encompassing genetic changes at the tumor level potentially affecting drug 
response (Amstutz et al., 2011). Whether they are somatic or found in the germline, all these 
mutations can potentially have deleterious impacts on the clinical outcome of patients with 
CRC cancer. At the tumor level, genetic changes affecting the expression of pharmacological 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
260 
targets or downstream signaling pathways can lead to treatment failure, as highlighted by 
the now canonical KRAS mutational status in patients undergoing anti-EGFR therapies. 
Constitutive mutations are mostly associated with increased toxic risk, as largely publicized 
by the dihydropyrimidine dehydrogenase (DPD) deficiency syndrome, a condition that puts 
5-FU patients at risk of life-threatening toxicities. Of note, when not directly life-threatening, 
inherited genetic mutations affecting drug disposition in the body and pharmacokinetics 
can ultimately lead to treatment failure too, because the induced-toxicities often require 
discontinuation of the treatments until the patient recovers. For all these reasons, 
developing pharmacogenetic and pharmacogenomic testing in routine clinical practice is 
now seen as a major issue in oncology. 
2. Pharmacogenomics: A matter of life & death at the tumor level 
2.1 Cytotoxics: Why should we not forget that they are targeted therapies too 
Standard care of colorectal cancer includes the use of a variety of cytotoxic agents, used 
either alone or more frequently as part of combinations (e.g., the canonical Folfiri and 
Folfox4 regimen). Each of these drugs have their own specific target (e.g., thymidylate 
synthase for 5-FU, DNA for oxaliplatin, topoisomerase I for irinotecan) and in this respect, 
numerous studies have focused on the deregulations affecting these targets, either at the 
genetic or the molecular level, as an attempt to predict treatment efficacy. Indeed, variations 
in the expression level of the targeted protein, polymorphisms inducing conformation 
changes, or increase in the repair systems/salvage pathways have been identified as major 
causes for treatment failure in mCRC patients. 
2.1.1 5-FU & Oral 5-FU: The older, the better 
5-FU remains the pivotal drug for treating CRC. Initially used alone, it soon turned to be 
systematically associated with folinic acid so as to enhance its effect as an antimetabolite, 
before being introduced as the backbone of several polychemotherapies including irinotecan 
(a.k.a. Folfiri regimen) or oxaliplatin (a.k.a. Folfox regimen). 5-FU’s main target is 
thymidylate synthase (TS), an enzyme essential to the DNA synthesis and cell replication. 
Several genetic polymorphisms can affect both TYMS, the gene coding for TS, and the folate 
cycle necessary for the synthesis of methylene tetrahydrofolate, the cofactor required for a 
complete inhibition of the target through the formation of a stable ternary complex between 
the enzyme, the cofactor, and fluorodeoxyuridine monophosphate (FdUMP). TS 
overexpression in tumors is generally associated with resistance to 5-FU treatment, both in 
vitro and at the bedside (Popat et al., 2004, Lenz et al., 2004). Conversely, another pivotal 
study has demonstrated that higher TS expression was predictive of higher response with 
adjuvant fluoropyrimidine (Edler et al., 2002). However, other clinical reports failed in 
demonstrating such relationship (Locker et al., 2006, Lurje et al., 2009), thus preventing 
substantial step to be undertaken for implementing screening for TS expression in tumors in 
routine clinical practice. Variations in TS expression are, at least in part, related to mutations 
affecting the TYMS gene promoter. For instance, the TSER*3 genotype has been associated 
with increased mRNA production, thus potentially leading to lower response rates in mCRC 
patients treated with 5-FU (Uetake et al., 1999). Beside the issue of over-expressing TS 
tumors likely to resist to 5-FU, constitutive polymorphisms in the 5’ and 3’UTRs of the 
TYMS gene responsible for downregulation of TS, have been associated with increased 
toxicities in patients treated with 5-FU or oral capecitabine (Larguiller et al., 2006). However, 
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as for TS expression level in tumors, the actual clinical relevance of these polymorphisms is 
far from being consensual. Lower response rates have been reported in colorectal cancer 
patients with the TS 5'-UTR 3R genotypes (ie, TSER*3), as compared to individuals harboring 
the homozygous TS 5'-UTR 2R/2R genotype (Salgado et al., 2007). Of note, other groups 
(Stoehlmacher et al., 2004, Kostopoulos et al., 2009) failed in observing any significant 
difference in the clinical outcome according to the TS 5'-UTR genotypes, whereas conversely, 
other authors (Jakobsen et al., 2005; Dotor et al., 2006) found longer survival in carriers of TS 5'-
UTR 3R genotypes as compared with those carrying the TS 5'-UTR 2R/2R genotypes. Such 
conflicting results for predicting outcome from TYMS genomic status is not surprising. Several 
factors such as genetic and epigenetic regulations may interfere with the genotype-to-
phenotype relationships (Pullmann et al., 2006). For instance, the loss of heterozygosity in 
tumours at the TS locus may cause the heterozygous TS 5'-UTR 2R/3R risk genotype to 
acquire either the 2R/loss or the 3R/loss genotype. Consequently, individuals theoretically at 
risk of treatment failure on the basis of their TS 5'-UTR 2R/3R genomic status may harbor 
actually the favorable 2R/loss genotype in cancer cells and exhibit higher response eventually 
when treated with 5-FU (Ruzzo et al., 2007). In addition to target TS, other non-synonymous 
SNPs (677C>T: MTHFR*4 and 1298A>C:MTHFR*6 allelic variants) affecting methylene 
tetrahydrofolate reductase (MTHFR), one of the key-enzyme involved in the synthesis of 
reduced folate cofactor, could lead to lack of efficacy when down-regulated (Etienne-Grimaldi 
et al., 2007, Zintsaras et al., 2009, Braun et al., 2009). However, as for TYMS, the actual impact 
of MTHFR genetic polymorphisms on the clinical outcome with 5-FU or 5-FU-derivatives 
remains to be fully elucidated because inconsistent data have been generated so far (Sharma et 
al., 2008, Ruzzo et al., 2007). All these contradictory findings with TYMS and the associated 
MTHFR genomic status are better understood when one keeps in mind that TS is not the main 
locus of action of 5-FU. Incorporation into RNA and DNA can be alternative mechanisms of 
actions for the cytotoxic effects of 5-FU, depending on the way the drug will be metabolized 
within tumor cells (Ciccolini et al., 2000a). In this respect, the expression levels of 
activating/deactivating enzymes at the tumor level (eg, orotate phosphoribosyl transferase, 
thymidine kinase, thymidine phosphorylase, dihydropyrimidine dehydrogenase) have been 
associated with clinical outcome in patients treated with 5-FU-containing regimen, although 
once again the data collected so far proved to be rather conflicting (Ciccolini et al., 2004; Soong 
et al., 2008). For instance, thymidine kinase is implicated both in the activation of 5-FU to 
active metabolite FdUMP with subsequent theoretical better TS inhibition if highly expressed, 
and in the de novo salvage pathway likely to help cancer cells to survive to 5-FU-induced 
thymineless stress (Fanciullino et al., 2007). Similarly, thymidine phosphorylase (TP) is 
involved in the tumoral activation of both 5-FU and capecitabine, but could promote 
neoangiogenesis too, thus rendering the clinical impact of TP levels in tumors hardly 
predictable (Ciccolini et al., 2004). Furthermore, deregulation of downstream proteins involved 
in the transmission of apoptosis in cells exposed to thymineless stress can affect 5-FU or 
capecitabine antiproliferative efficacy, despite proper inhibition of target TS. Because 5-FU 
exerts its cytotoxic effects partly through a p53/Fas-dependent apoptotic pathway involving 
Bax translocation and mitochondrial permeabilization, deregulations affecting each of these 
steps can interfere with the actual upstream TYMS status or the extent of TS inhibition 
(Borralho et al., 2007). For instance, down-expression of Apo-1 Fas CD95 receptor has been 
associated with resistance to 5-FU or capecitabine in non-clinical colorectal models, including 
after that a near-total inhibition of TS activity was achieved (Ciccolini et al., 2000b; 2001). 
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However, subsequent clinical studies failed in demonstrating the role Fas expression could 
play as a predictive marker in patients with colorectal cancer (Backus et al., 2001; Bezulier et 
al., 2003). 
2.1.2 Oxaliplatin: A metal precious to the patients 
In clinical practice, oxaliplatin is given in mCRC patients in association with 5-FU/folinic 
acid, a combination known as the Folfox regimen. It can be further combined now with the 
latest monoclonal antibodies targeting VEGF or EGFR-1. Oxaliplatin is a third-generation 
platinum derivative that targets complementary DNA strands, thus inducing cell death 
eventually. However, the nucleotide excision repair (NER) system is designed to remove the 
oxaliplatin-induced DNA-adducts, and several factors (XPD (a.k.a. ERCC2), XPC and XPA) 
are implicated in the repair process of DNA helixes once adducts have been formed. In 
addition, XPG and ERCC1 are implicated in the cleavage of the damaged DNA strand and 
participate to the repairing pattern of cells exposed to oxaliplatin. Any changes in those 
repair mechanisms can lead to increase of sensitivity or loss of efficacy in patients. Several 
genotypes at the tumor level have been associated with clinical outcome in oxaliplatin-
regimen. In particular, it has been demonstrated that polymorphisms affecting ERCC1 and 
XPD genes are related to patient survival. For instance, ERCC1-118 T/T, or XPD-751 A/C 
and C/C genotypes have been associated with reduced disease-free survival in patients 
treated with oxaliplatin (Ruzzo et al., 2007). In another study, the Lys751Gln polymorphism 
of the XPD gene has been identified as a predictive marker in mCRC patients undergoing 
FolFox treatment (Le Morvan et al., 2007). Beside the NER, basepair excision repair is also 
involved in the chemosentivity to oxaliplatin. XRCC1 gene is affected by several 
polymorphisms, and expression of the wild-type allele has been associated with better 
clinical outcome in patients with mCRC (Suh et al., 2006, Stoehlmacher et al., 2001), 
although subsequent studies failed in confirming the relevance of establishing XRCC1 
genotype as a predictive biomarker with oxaliplatin (Ruzzo et al., 2007). Along with the 
issue of efficacy, mutations affecting Glutathione-S Transferase (GST), the enzyme 
responsible for the cell detoxification of oxaliplatin, could have an impact on the clinical 
outcome with oxaliplatin. Overexpression of tumoral GSTP1 has been found in CRC 
patients, thus leading to lack of efficacy (Glasgow et al., 2005). However, the exact role the 
genetic status GSTP1 plays in patients treated with oxaliplatin remains controversial. For 
instance, the GSTP1 ile105val genotype has been associated with improved survival in 
patients treated with Folfox regimen (Stoehlmacher et al., 2002), although the same 
genotype was predictive of reduced survival in another study (Sun et al., 2005) . In addition, 
the GSTP1-105 G allele, could explain higher incidence of severe neurotoxicities, the most 
common side-effect of oxaliplatin, observed in some patients (Ruzzo et al., 2007). Another 
polymorphism affecting the AGXT gene coding for the enzyme responsible for the 
metabolism of oxalate, which peaks during oxaliplatin infusion, could explain higher risk of 
neurotoxicity in patients (Gamelin et al., 2007).  
2.1.3 Irinotecan: Twist again ‘till double-strand DNA breakage 
Irinotecan (CPT-11) is a topoisomerase-I (Topo-1) inhibitor usually combined with 5-
FU/folinic acid regimen, an association known as the FolFiri regimen. Topo-1 relieves 
torsional strain in DNA, thus allowing DNA replication, recombination, and repair. 
Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA 
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complex, thus causing double-strand DNA breakage and cell death eventually. Expression 
levels of target topo-I has been associated with clinical outcome in multivariate analysis 
performed from large studies including several hundreds of patients undergoing irinotecan-
based therapy (Braun et al., 2008; Kostopoulos et al., 2009). However, the lack of 
randomized, prospective trial prevents, for the time being, the evaluation of Topo-1 level in 
tumours to be proposed in routine clinical setting as a predictive biomarker for irinotecan 
efficacy, and little is known about the genetic or epigenetic events affecting the Topo-1 gene 
likely to modify expression levels of the target protein. However, in the Focus trial, Topo-1 
expression level was found to be related to efficacy, although it remains unclear whether the 
expression level is to be considered as a predictive or a prognostic marker (Braun et al., 
2008). In addition, as for oxaliplatin, deregulations affecting DNA-repairing enzymes like 
XRCC1, ERCC1 and GSTP1 have been found to be predictive of the clinical outcome in 
irinotecan-treated patients. Polymorphism affecting the XRCC1 gene (eg, the GGCC-G 
haplotype) was associated with improved response rates in patients given irinotecan, much 
probably in relation with loss of ability to repair DNA damage (Hoskins et al., 2008). 
Conversely, better response and, in some cases, improved PFS was observed in patients 
undergoing FolFiri regimen with tumors overexpressing GSTP1 and ERCC1 (Vallbohmer et 
al., 2006). This finding may be confusing because higher expression in DNA-repair enzymes 
is normally associated with resistance to DNA-targeting agents. Here, high ERCC1 levels 
could be indicative of a higher DNA damage, thus making the tumor cells more sensitive to 
Topo-I inhibition by irinotecan. In the same study, EGFR expression was found to be 
associated too with better response, although to date, no molecular mechanisms underlying 
this observation have been found.  
2.2 Biotherapies: Where are my keys?  
Treatment of colorectal cancer has taken benefit from the rise of the biotherapies in clinical 
oncology, because both anti-VEGF and anti-EGFR monoclonal antibodies can be used now 
in association with cytotoxics agents. However, the efficacy of most targeted therapies is 
generally contingent upon a number of biomarkers at the tumor level to be checked. 
2.2.1 Anti-EGFR monoclonal antibodies: Why hitting the target is not enough  
Cetuximab and panitumumab are two anti-Her1 monoclonal antibodies indicated for 
treating metastatic colorectal cancer. Initially proposed alone, both drugs showed better 
efficacy and improved survival when combined with standard Folfox4 or Folfiri regimen. 
Although cetuximab is a chimeric IgG1 and panitumumab a 100% human IgG2, these both 
antibodies target the extracellular domain of EGFR-1, thus blocking the downstream 
signaling pathway normally leading to cell proliferation and differenciation, 
neoangiogenesis and invasion patterns associated with colorectal cancer. Cetuximab and 
panitumumab prescription is contingent upon the completion of pharmacogenomics testing. 
Expression level of target EGFR is the first condition, although in clinical practice, the 
relevance of this test is more and more debated and controversial at the bedside. However, 
several studies have demonstrated how patients with elevated EGFR gene copy number are 
more likely to respond to cetuximab or panitumumab therapy (Moroni et al., 2005; Sartore-
Bianchi et al., 2007, Heinemann et al., 2009). More interestingly and consensual, 
determination of the mutational status of KRAS soon turned to be the paradigm of 
implementing pharmacogenomic testing prior to initiating treatment with a targeted 
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therapy. The EGFR/KRAS/Raf pathway is implicated in signal transduction from receptors 
to the nucleus, thus promoting cell proliferation and differentiation. KRAS transmits signal 
after binding to guanosine triphosphate (GTP), and becomes inactive when GTP is 
converted to GDP. Mutations affecting KRAS will maintain the protein continuously 
activated in a switch-on position, even if the upstream receptor is inhibited by a monoclonal 
antibody. It was demonstrated in the mid-2000’s that specific KRAS mutations (eg, codons 
12/13) was associated with lack of response in cetuximab-treated patients (Lievre et al., 
2006). Subsequent studies all confirmed the predictive value of wild-type (WT) KRAS for the 
response with anti-EGFR biotherapies, either cetuximab or panitumumab, regardless of 
their use as monotherapy or combined with cytotoxics (Heinemann et al., 2009, Asghar et 
al., 2010). However, WT KRAS is a mandatory but no sufficient condition to guarantee an 
optimal efficacy with anti-EGFR therapies. Mutations affecting BRaf, an effector of KRAS, 
has been associated with treatment failure, although it remains unclear whether BRaf 
mutational status should be used as a prognostic or a predictive marker (Di Nicolantonio et 
al., 2008). Similarly, correlation was found in cetuximab-treated patients between EGFR 
gene amplification, WT KRAS status, PTEN expression, and response. Of note, loss of PTEN 
expression was systematically associated with treatment failure, thus suggesting that PTEN 
could be a novel predictive biomarker for anti-EGFR therapies (Frattini et al., 2007). Along 
with PTEN, several other parameters like epiregulin and amphiregulin expression have 
been recently identified as putative biomarkers (Jacobs et al., 2009; Laurent-Puig et al., 2009; 
Di Fiore et al., 2010), although larger prospective studies will be necessary to validate their 
clinical relevance to predict clinical outcome with EGFR-inhibitors.  
2.2.2 Anti-VEGF therapy: Desesperatly seeking biomarkers 
Bevacizumab is the only stricto-sensu antiangiogenic therapy approved for treating mCRC 
patients in association with cytotoxics. This humanized monoclonal antibody targets 
circulating VEGF-A. To date, no predictive biomarkers have been identified with 
bevacizumab. Overexpression of VEGF is usually associated with poor survival in mCRC 
patients, but VEGF level is generally considered as a prognostic, rather than a predictive, 
biomarker. Even in a prognostic setting, the actual role VEGF polymorphism plays remains 
unclear. For instance, in some studies, the -460CC genotype was found to have a favorable 
impact on OS in gastric cancer patients (Kim et al., 2007), but deleterious in breast cancer 
patients (Lu et al., 2005). Beside, some studies in breast cancer patients have found a 
relationship between VEGF polymorphisms (eg, -2578A/A and -1154A/A genotypes) and 
better survival in patients treated with the paclitaxel + bevacizumab regimen (Schneider et 
al., 2008). Similar relationship between VEGF-A polymorphism and both toxicity and DFS 
has been evidenced more recently (Etienne-Grimaldi et al., 2010). A similar trend has been 
found with digestive cancers (Formica et al., 2010). Additionally, circulating PDGF could be 
implicated in resistance to anti-angiogenic drugs (Crawford et al., 2009), as well as SDF1 and 
FGF2 factors (Batchelor et al., 2007). Finally, plasma cytokines and vascular factors could be 
associated with clinical outcome in patients undergoing bevacizumab-based therapy 
(Kopetz et al., 2010). However in a recent study, Loupakis et al. have investigated the 
molecular and genetic markers likely to predict efficacy in mCRC patients treated with the 
Folfoxiri plus bevacizumab quadruple combination. Among the various bevacizumab-
related biomarkers they monitored in plasma (ie VEGF, PIGF, sVEGFR2, TSP-1 plasma 
level) and the screening of several polymorphims affecting VEGF (eg., -2578C/A, -1498C/T, 
-1154G/A, 936C/T) and VEGFR-2 (-604A/G, 1192C/T, 1719T/A), little relevant association 
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with PFS was found (Loupakis et al., 2011). This latter study illustrates the difficulty in 
identifying relevant biomarkers for response in heavily treated mCRC patients receiving 
several drugs in a row, the observed efficacy being the resulting combination of the 
numerous parameters affecting each drug.  
3. Pharmacogenetics: When genetics help finding the right exposure 
3.1 Cytotoxics: Improving the efficacy/toxicity balance 
Beside those affecting tumors, several constitutive genetic mutations can impact on the 
disposition of anticancer drugs, especially when they concern genes coding for detoxifying 
enzymes in the liver. Although for years, such polymorphisms were mostly associated with 
increased risk of developing severe and sometimes deadly toxicities upon drug intake, they 
may impact as well on treatment efficacy eventually. Indeed, when they are not directly life-
threatening, drug-induced toxicities and their management often require treatment 
discontinuation, delays in subsequent radiotherapy courses if scheduled, with a subsequent 
loss of chance and poor clinical outcome eventually. 
3.1.1 5-FU & Oral 5-FU 
Fluoropyrimidines pharmacokinetics is primarily dependent upon an intense liver first pass 
effect mediated by dihydropyrimidine dehydrogenase (DPD), the enzyme that converts 
uracil into dihydrouracil. It is generally estimated that about 90-95% of an administered 5-
FU dose will be metabolized in the liver before being distributed throughout the body. DPD 
exhibits a similar pivotal role in the disposition of oral fluoropyrimidines like capecitabine 
or UFT, all generating 5-FU eventually. DPYD gene is highly polymorphic because several 
dozen of mutations have been described thus far (Van Kuilenburg, 2004). Mutational 
inactivation of the DPYD gene has been characterized as an autosomal recessive disease in 
Caucasians’ population, with probably a higher impact in black American (Mercier C et al., 
2006). Genetic and epigenetic regulations, such as promoter hypermethylation or variations 
in transcriptional factor expression, could play as well a critical role in DPYD dysregulations 
(Etienne MC et al., 1994, Zhang et al., 2006), although this issue remains debated today. 
Admittedly, three relevant mutations (canonical IV14+1G>A (DPYD*2A), plus 2846A>T, 
and 1679T>G) should be screened at bedside to anticipate 5-FU-related side effects (Morel et 
al., 2006). Numerous clinical reports have demonstrated the deleterious effect of DPD 
genetic polymorphism in patients undergoing 5-FU based regimen. Regardless of the 
upstream genetic events leading to the loss of enzymatic activity, impaired DPD has been 
systematically associated with increased risk of developing severe/lethal toxicities upon 5-
FU exposure. In a proof-of-concept study, DPD deficiency was retrospectively identified as 
the culprit for 70% of the severe toxicities and 80% of the toxic-death cases monitored over a 
two-year observation period, and when performed, drug monitoring confirmed strong 
overexposure to 5-FU in DPD-deficient individuals (Ciccolini et al., 2006). However, some 
reports failed in providing data for this pivotal role DPYD genetic polymorphism could play 
in the incidence of severe toxicities with 5-FU. In a gene-candidate study, Schwab et al. have 
investigated the role several polymorphisms, including the DPYD*2A allelic variant, could 
play in the tolerance to 5-FU. Surprisingly, this genotype was found to be only marginally 
associated with toxicities, but it has to be underlined that in this study, no complementary 
functional investigations were undertaken to evaluate globally the DPD status in those 
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patients (Schwab et al., 2008). In addition to 5-FU, several reports have suggested that DPYD 
genetic polymorphism could be an issue with capecitabine too. The very first toxic-death 
case has been first observed in the late-2000’ in a patient treated with capecitabine who was 
found to be profoundly DPD deficient after post-mortem investigations (Mercier et al., 
2007a). Several other clinical reports have demonstrated how DPYD genetic polymorphism 
could put deficient patients at risk of experiencing severe toxicities if given capecitabine 
(Mercier et al., 2007b). Lastly, another genetic polymorphism could be a rising concern with 
capecitabine. Deregulations affecting cytidine deaminase (CDA), one of the three enzymes 
responsible for the conversion of prodrug capecitabine to 5-FU, could lead to severe 
toxicities. As for DPD, the gene coding for CDA is highly polymorphic with either loss (poor 
metabolizer) or gain (ultra-metabolizer, UM) of enzymatic activity. The first life-threatening 
toxicity in a patient displaying the UM phenotype was reported in the late 2000’s (Mercier C 
et al., 2009). The role CDA could play in severe toxicities with capecitabine has been next 
confirmed in another larger study showing that deletion in the promoter region of the CDA 
gene with increased transcription was a predictive marker for hand-foot syndrome (Caronia 
et al., 2011). Lastly, the first toxic-death case in a capecitabine-treated patient harboring 
several polymorphisms on the CDA gene, including the Caronia deletion, has been 
published recently (Dahan et al., 2011), thus highlighting the fact that beside DPYD, other 
genetic polymorphisms should be screened to ensure a better safety when handling oral 
fluoropyrimidines. 
3.1.2 Irinotecan 
Irinotecan is a prodrug that can be either metabolized by the Cyp3A sub-family to form the 
inactive APC derivative, or be converted by carboxylesterase into SN38, a highly cytotoxic 
metabolite responsible for both the efficacy and the toxicity of irinotecan. SN38 is next 
mainly detoxified after conjugation by the UGT1A1 to yield inactive SN-38G that will be 
excreted by the kidneys and the bile eventually. Numerous polymorphisms have been 
described for the gene coding for UGT1A1, and variations in the promoter region consisting 
in 7 instead of 6 TA-repeats (UGT1A1*28) is admittedly associated with increased risk of 
severe toxicities in mCRC patients administered with high dose (e.g., above 250 mg/m2) 
irinotecan (Kweekel et al., 2010). A strong influence of ethnicity has been observed with this 
allelic variant because its population frequency is as high as 43% heterozygotes in the 
Caucasians but much lower in the Asians (Innocenti et al., 2005; deJong et al., 2006). Several 
independent studies have demonstrated how individuals with the UGT1A1*28 genotype 
were up to 7-time more at risk to experience haematological or gastrointestinal severe 
toxicities when treated with irinotecan (Ando et al., 2000; Marcuello et al., 2004). Of note, 
some authors have reported an association between the UGT1A1*28 genotype and 
irinotecan efficacy (Toffoli et al., 2006), although other studies have failed in providing 
evidence for such a relationship (Kweekel et al., 2008). Along with the UGT1A1*28 
genotype, other variations such has the UGT1A1*6 most frequently found in Asian 
populations has been associated with increased severe neutropenia after irinotecan intake 
(Han et al., 2006), although other studies failed in confirming such relationship (Ando et al., 
2000). Additionally, polymorphisms affecting transmembrane pumps involved in the 
excretion of toxic metabolites could be related to drug resistance. Pharmacogenetics of the 
ATP-binding cassette proteins has been associated with changes in the pharmacokinetics of 
irinotecan, because they impact of the renal clearance of the drug and ultimatelly on 
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exposure levels. For instance, patients harboring the 34A>G SNP on the ABCG2 gene could 
be more at risk of treatment failure, as compared with WT patients (Mc Leod et al., 2008). 
Conversely, other SNPs like the 421C>A polymorphism seems to have limited impact on 
irinotecan pharmacokinetics and clinical outcome (de jong et al., 2004) whereas some 
mutations were associated with higher incidence of drug-induced toxicities (Cha et al., 
2009).  
3.2 Pharmacokinetics of targeted therapies: The hidden biomarker?  
For years, the importance of pharmacokinetic issues such as residual plasma levels or drug 
concentrations at the tumor site has been largely underestimated with targeted therapies. 
For instance, it took 5 years since its first approval in Chronic Myeloid Leukemia to 
acknowledge the fact that the residual concentrations of imatinib were predictive for the 
major molecular response in patients, thus highlighting the utility to perform drug 
monitoring and subsequently developing dose-tailoring strategies to ensure a better efficacy 
(Egorin et al., 2009). Although similar strategies are now developed with other small 
molecules such as pazopanib (Suttle et al., 2010), no such trend is currently proposed with 
monoclonal antibodies, despite the fact that dose/exposure/efficacy and 
dose/exposure/toxicities relationships have been described (Lu et al., 2009, Keiser et al., 
2010). Both non-clinical and clinical studies suggest that 90% of target inhibition should be 
continuously achieved to ensure a maximum efficacy, thus stressing the usefulness to 
monitor residual concentrations of monoclonal antibodies such as panitumumab, as for 
other target therapies (Yang et al., 2010). For instance, plasma residual concentrations of 10-
30 ug/ml are considered necessary with bevacizumab for an optimal efficacy (Data on File 
Genentech Inc). However, little is known about the pharmacokinetics of monoclonal 
antibodies and there is a clear lack for markers of inter-patient variability. Proteolytic 
degradation along with target-mediated drug disposition are the main patterns implicated 
in the clearance of monoclonal antibodies, and several factors such as antibodies anti-
therapeutic antibodies, target expression, number of metastatic sites or inflammatory 
syndromes are likely to modify drug levels in plasma. Of note, genetic polymorphism 
affecting immunoglobulin G fragment receptor Fc--R has been identified as a putative 
marker for rituximab clearance, but the clinical importance of Fc--R genotype could be 
more related to the Antibody-Dependent Cell Cytotoxicity (ADCC) of rituximab that 
involves Fc--R, rather than a pharmacokinetics issue (Cartron et al., 2002). In digestive 
oncology, Fc--R genotype has been identified in mCRC patients treated with cetuximab as 
predictive for PFS, but as for rituximab, this could be related to changes in the ADCC 
described sometimes with cetuximab rather than changes in pharmacokinetics (Zhang et al., 
2007), and other studies failed in confirming the impact this polymorphism could have with 
the anti-EGFR therapy (Graziano et al., 2008). 
4. Conclusions: One patient, one disease, one drug, one dosage…. Can we 
finally do it?  
Developing strategies to implement personalized medicine in digestive oncology is now an 
irreversible trend (Ciccolini et al., 2011). However, identifying predictive biomarkers 
associated with either treatment efficacy or tolerance remains an uneasy task, because CRC 
patients are usually treated with up to 6 different drugs in combination over several lines. 
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Consequently, and despite the abundant literature published, the heterogeneity in the 
clinical settings can hinder the relevance of some markers, thus preventing standardized 
guidelines to be issued. However, oncogenetic, pharmacogenetic and pharmacogenomic 
tools are now developed as a new mean to help oncologists to choose the optimal strategy 
for each patient, regarding the staging of the disease, the status of the various response 
markers, and eventually information about specificities in pharmacokinetics and 
detoxification patterns, once the right drugs have been chosen. However, this later and 
critical step remains today the forgotten item in routine clinical setting. Although 
implementing KRAS pharmacogenomic testing is now a systematic practice prior to 
administrate cetuximab or panitumumab to mCRC patients, little is done to further develop 
pharmacogenetics-based dose tailoring strategies to reach next the right exposure likely to 
ensure an optimal efficacy/toxicity balance. Screening for DPYD or UGT1A1 genetic 
polymorphisms, despite countless clinical reports demonstrating their role in life-
threatening toxicities, and therefore the usefulness of preliminary testing in patients 
undergoing 5-FU, capecitabine or irinotecan-based regimen to anticipate treatment-related 
toxicities, is far from being a common practice. However, when performed, 
pharmacoeconomic studies suggest that implementation of such screening is cost-effective, 
thus suggesting that routine pharmacogenetics should benefit both to the patients and to the 
institute ultimately, by dramatically cutting the costs dedicated to managing the treatment-
related toxicities (Mercier et al., 2009). Of note, no regulatory official step has been 
undertaken to date to prompt oncologists to require such tests when prescribing cytotoxics 
to mCRC patients. Changes in the drug label informing physicians about the toxic risks with 
irinotecan related to the UGT1A1 genetic polymorphism has been done by the F.D.A in the 
mid-2000’s and official warning issued as a as a level-2 priority, but with little impact in 
clinical practice, partly because the UGT1A1 test is not reimbursed in the U.S. by most 
insurance companies (Ikediobi et al., 2009, Meckley et al. 2010), and partly because of the 
lack of tools to customize the irinotecan dosage once the UGT1A1 status has been obtained. 
As of today, it is acknowledged that the UGT1A1*28 genotype is a concern in patients 
scheduled for irinotecan dosage above 200 mg/m² only, with little further guidelines made 
available about adaptive dosing strategies to treat patients harboring this polymorphism 
(Hoskins et al., 2007) because. Usually, an empirical 25-50% reduction in irinotecan starting 
dose is recommended in patients with the homozygous variant. Similarly, screening for 
DPYD genetic polymorphism is an exceptional, rather than a routine test in most institutes. 
DPD testing can be required at best once the severe toxicities have already shown in a 
patient treated with a 5-FU-containing regimen to keep or discard the fluoropyrimidine in 
the forthcoming course. As for UGT1A1, little tools are available to tailor dosage based upon 
the DPD status of the patient. However, a case-control study has demonstrated the 
immediate advantages patients could benefit from prospective DPD testing associated with 
adaptive-dosing, with a sharp reduction in the incidence of 5-FU-related toxicities in 
patients screened for DPD deficiency with tailored dosage as compared with patients 
treated with standard regimen (Yang et al., 2009). Of note, efficacy remained the same in this 
study despite markedly lower doses in patients with DPD deficiency, thus illustrating how 
pharmacogenetics-based adaptive dosing could improve indeed the efficacy/toxicity 
balance of canonical 5-FU. In this respect, prospective clinical trials investigating 
pharmacogenetics of drugs given in mCRC patients with strong PK, PK/PD and 
www.intechopen.com
Pharmacogenetics and Pharmacogenomics  
of Colorectal Cancer: Moving Towards Personalized Medicine 
 
269 
PK/PD/PGx modeling support should help to develop easy-to-implement tools designed to 
individualize dosing based upon the patients genotypes or phenotypes.  
5. References 
Amstutz U, & Carleton BC. (2011). Pharmacogenetic testing: time for clinical practice 
guidelines. Clin Pharmacol Ther, Vol. 89, N°6, pp.924-7. 
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, & 
Hasegawa Y. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and 
irinotecan toxicity: a pharmacogenetic analysis. Cancer Res, Vol. 60, N°24, pp.6921-6. 
Asghar U, Hawkes E, & Cunningham D. (2010) Predictive and prognostic biomarkers for 
targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer, Vol. 9, N°5, 
pp.274-81. 
Backus HH, Dukers DF, van Groeningen CJ, Vos W, Bloemena E, Wouters D, van Riel JM, 
Smid K, Giaccone G, Pinedo HM, & Peters GJ. (2011) 5-Fluorouracil induced Fas 
upregulation associated with apoptosis in liver metastases of colorectal cancer 
patients. Ann Oncol, Vol. 12, N°2, pp.209-16. 
Batchelor T, et al. (2007). AZD 2171, a pan-VEGF receptor tyrosine kinase inhibitor, 
normalizes tumor vasculature and alleviates edema in glioblastoma patients. 
Cancer Cell, Vol. 11, N°6, pp.83-95. 
Bezulier K, Fina F, Roussel M, Bun SS, Ciccolini J, Martin PM, Milano G, Aubert C, & Barra 
Y. (2003). Fas/FasL expression in tumor biopsies: a prognostic response factor to 
fluoropyrimidines? J Clin Pharm Ther, Vol. 28, N°5, pp.403-8. 
Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C, Nobre Leitão C, Steer CJ, & 
Rodrigues CM. (2007). Inhibition of Fas expression by RNAi modulates 5-
fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. Biochim 
Biophys Acta, Vol. 1772, N°1, pp.40-7. 
Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar 
MK, Quirke P, & Seymour MT. (2009). Association of molecular markers with 
toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal 
cancer: the FOCUS trial. J Clin Oncol, Vol. 27, N°33, pp.5519-28.  
Caronia D, Martin M, Sastre J, de la Torre J, García-Sáenz JA, Alonso MR, Moreno LT, Pita 
G, Díaz-Rubio E, Benítez J, & González-Neira A. (2006). A polymorphism in the 
cytidine deaminase promoter predicts severe capecitabine-induced hand-foot 
syndrome. Clin Cancer Res, Vol. 17, N°7, pp.2006-13 
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, & Watier H. (2002). 
Therapeutic activity of humanized anti-CD20 monoclonal antibody and 
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, Vol. 99, N°3, pp.754-8. 
Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, Shimoyama R, 
Nishidate T, Furuhata T, Sasaki K, Hirata K, & Nakamura Y. (2009). Single 
nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe 
myelosuppression. J Hum Genet, Vol. 54, N°10, pp.572-80. 
Ciccolini J, Peillard L, Aubert C, Formento P, Milano G, & Catalin J. (2000a). Monitoring of 
the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 
human colon cell line: application to modulation of metabolism and cytotoxicity 
study. Fundam Clin Pharmacol, Vol. 14, N°2, pp.147-54. 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
270 
Ciccolini J, Peillard L, Evrard A, Cuq P, Aubert C, Pelegrin A, Formento P, Milano G, & 
Catalin J. (2000b). Enhanced antitumor activity of 5-fluorouracil in combination 
with 2'-deoxyinosine in human colorectal cell lines and human colon tumor 
xenografts. Clin Cancer Res, Vol. 6, N°4, pp.1529-35. 
Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, Cano JP, & Iliadis A. 
(2001). Combination of thymidine phosphorylase gene transfer and deoxyinosine 
treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. 
Mol Cancer Ther, Vol. 1, N°2, pp.133-9. 
Ciccolini J, Evrard A, & Cuq P. (2004). Thymidine phosphorylase and fluoropyrimidines 
efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents, Vol. 4, N°2, 
pp.71-81. 
Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Lacarelle B, & Seitz JF. 
(2006). A rapid and inexpensive method for anticipating severe toxicity to 
fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit, Vol. 28, 
pp.678-85. 
Ciccolini J, Mercier C, Dahan L, & André N. (2011). Integrating pharmacogenetics into 
gemcitabine dosing-Time for a change? Nat Rev Clin Oncol, Vol. 8, N°7, pp.439-44. 
Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, & Ferrara N. (2009). 
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts 
associated with tumors refractory to anti-VEGF treatment. Cancer Cell, Vol. 15, N°1, 
pp.21-34. 
Dahan L, Ciccolini J, Evrard A, Mbatchi L, Tibbits J, Ries P, Norguet E, Mercier C, Iliadis A, 
Ouafik LH, Lacarelle B, & Seitz JF. (2011) Sudden toxic-death in a patient upon 
Xeliri (capecitabine + irinotecan) plus bevacizumab intake: pharmacogenetics 
implications. J Clin Oncol, Vol. 29, E-Pub ahead of Print. 
de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, & McLeod HL. 
(2004). ABCG2 pharmacogenetics: ethnic differences in allele frequency and 
assessment of influence on irinotecan disposition. Clin Cancer Res, Vol. 10, N°17, 
pp.5889-94. 
de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting 
AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, & de 
Jonge MJ. (2006). Prophylaxis of irinotecan-induced diarrhea with neomycin and 
potential role for UGT1A1*28 genotype screening: a double-blind, randomized, 
placebo-controlled study. Oncologist, Vol. 11, N°8, pp.944-54. 
Di Fiore F, Sesboüé R, Michel P, Sabourin JC, & Frebourg T. (2010). Molecular determinants 
of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer, 
Vol. 103, N°12, pp.1765-72 
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, 
Mazzucchelli L, Frattini M, Siena S, & Bardelli A. (2008). Wild-type BRAF is 
required for response to panitumumab or cetuximab in metastatic colorectal cancer. 
J Clin Oncol, Vol. 26, N°35, pp.5705-12.  
Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, 
Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, 
Capellá G, & Villanueva A. (2006). Tumor thymidylate synthase 1494del6 genotype 
as a prognostic factor in colorectal cancer patients receiving fluorouracil-based 
adjuvant treatment. J Clin Oncol, Vol. 249, N°10, pp.1603-11. 
www.intechopen.com
Pharmacogenetics and Pharmacogenomics  
of Colorectal Cancer: Moving Towards Personalized Medicine 
 
271 
Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, 
& Blomgren H. (2002). Thymidylate synthase expression in colorectal cancer: a 
prognostic and predictive marker of benefit from adjuvant fluorouracil-based 
chemotherapy. J Clin Oncol, Vol. 20, N°7, pp.1721-8. 
Egorin MJ, Mauro MJ, & Trent JC.(2009). Drug plasma monitoring in CML and GIST: A 
case-based discussion. Clin Adv Hematol Oncol, Vol. 7, N°11-S1, pp. S3-11. 
Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, & Milano G. (1994). 
Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin 
Oncol, Vol. 12, N°11, pp.2248-53. 
Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Dalenc F, 
Espié M, Veyret C, Formento JL, Francoual M, Piutti M, de Crémoux P, & Milano 
G. (2011). Prospective analysis of the impact of VEGF-A gene polymorphisms on 
pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer 
patients. Br J Clin Pharmacol, Vol. 71, N°6, pp.921-8 
Etienne-Grimaldi MC, Francoual M, Formento JL, & Milano G. (2007). 
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based 
treatments in colorectal cancer. Pharmacogenomics, Vol. 8, N°11, pp.1561-6. 
Fanciullino R, Evrard A, Cuq P, Giacometti S, Peillard L, Mercier C, Aubert C, Milano G, & 
Ciccolini J. (2006). Genetic and biochemical modulation of 5-fluorouracil through 
the overexpression of thymidine kinase: an in-vitro study. Anticancer Drugs, Vol. 17, 
N°4, pp.463-70 
Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, 
Schirru M, Guadagni F, & Roselli M. Predictive value of VEGF gene 
polymorphisms for metastatic colorectal cancer patients receiving first-line 
treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis, 
Vol. 26, N°2, pp.143-51. 
Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, 
Etienne LL, Cavalli F, & Mazzucchelli L. (2007). PTEN loss of expression predicts 
cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer, Vol. 97, N°8, 
pp.1139-45. 
Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, Gilles S, Boisdron-Celle M, 
& Gamelin E. (2007). Predictive factors of oxaliplatin neurotoxicity: the 
involvement of the oxalate outcome pathway. Clin Cancer Res, Vol. 13, N°21, 
pp.6359-68. 
Glasgow SC, Yu J, Carvalho LP, Shannon WD, Fleshman JW, & McLeod HL. (2005). 
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. 
Br J Cancer, Vol. 92, N°2, pp.259-64. 
Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bisonni R, Torresi U, 
Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, 
Giustini L, Tonini G, Fontana A, Masi G, & Magnani M. (2008). Pharmacogenetic 
profiling for cetuximab plus irinotecan therapy in patients with refractory 
advanced colorectal cancer. J Clin Oncol, Vol. 26, N°9, pp.1427-34. 
Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, & Lee JS. (2006). 
Comprehensive analysis of UGT1A polymorphisms predictive for 
pharmacokinetics and treatment outcome in patients with non-small-cell lung 
cancer treated with irinotecan and cisplatin. J Clin Oncol, Vol. 24, N°11, pp.2237-44. 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
272 
Heinemann V, Stintzing S, Kirchner T, Boeck S, & Jung A. (2009). Clinical relevance of 
EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal 
antibodies directed against the EGFR. Cancer Treat Rev, Vol. 35, N°3, pp.262-71 
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, & McLeod HL. (2007). UGT1A1*28 genotype 
and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst, Vol. 99, N°7, 
pp.1290-5 
Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, 
Culverhouse R, McLeod HL, & Baiget M. (2008). Irinotecan pharmacogenetics: 
influence of pharmacodynamic genes. Clin Cancer Res, Vol. 14, N°6, pp.1788-96. 
Ikediobi ON, Shin J, Nussbaum RL, Phillips KA; UCSF Center for Translational and Policy 
Research on Personalized Medicine, Walsh JM, Ladabaum U, & Marshall D. (2009). 
Addressing the challenges of the clinical application of pharmacogenetic testing. 
Clin Pharmacol Ther, Vol. 86, N°1, pp.28-31. 
Innocenti F, Liu W, Chen P, Desai AA, Das S, & Ratain MJ. (2005). Haplotypes of variants in 
the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics, Vol. 
15, N°5, pp.295-301. 
Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, 
Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Pénault-Llorca F, De 
Hertogh G, Laurent-Puig P, Van Cutsem E, & Tejpar S. (2009). Amphiregulin and 
epiregulin mRNA expression in primary tumors predicts outcome in metastatic 
colorectal cancer treated with cetuximab. J Clin Oncol, Vol. 27, N°13, pp.5068-74 
Jakobsen A, Nielsen JN, Gyldenkerne N, & Lindeberg J. (2005). Thymidylate synthase and 
methylenetetrahydrofolate reductase gene polymorphism in normal tissue as 
predictors of fluorouracil sensitivity. J Clin Oncol, Vol. 23, N°7, pp.1365-9. 
Keizer RJ, Huitema AD, Schellens JH, & Beijnen JH. (2010). Clinical pharmacokinetics of 
therapeutic monoclonal antibodies. Clin Pharmacokinet, Vol. 49, N°8, pp.493-507. 
Kim JG, Sohn SK, Chae YS, Cho YY, Bae HI, Yan G, Park JY, Lee MH, Chung HY, & Yu W. 
(2007). Vascular endothelial growth factor gene polymorphisms associated with 
prognosis for patients with gastric cancer. Ann Oncol, Vol. 18, N°6, pp.1030-6. 
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero 
V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, & Heymach JV. (2010). 
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic 
colorectal cancer: efficacy and circulating angiogenic biomarkers associated with 
therapeutic resistance. J Clin Oncol, Vol. 28, N°3, pp.453-9. 
Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, 
Papakostas P, Vrettou E, & Fountzilas G. (2009). Topoisomerase I but not 
thymidylate synthase is associated with improved outcome in patients with 
resected colorectal cancer treated with irinotecan containing adjuvant 
chemotherapy. BMC Cancer, 2009 Sep 24; 9:339. 
Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, & Kalofonos 
HP. (2011). Targeted therapy in colorectal cancer: current status and future 
challenges. Curr Med Chem, Vol. 18, N°11, pp.1599-612. 
Kweekel DM, Gelderblom H, & Guchelaar HJ. (2005). Pharmacology of oxaliplatin and the 
use of pharmacogenomics to individualize therapy. Cancer Treat Rev, Vol. 31, N°2, 
pp.90-105. 
www.intechopen.com
Pharmacogenetics and Pharmacogenomics  
of Colorectal Cancer: Moving Towards Personalized Medicine 
 
273 
Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, & Guchelaar HJ; 
Dutch Colorectal Cancer Group study.(2008). UGT1A1*28 genotype and irinotecan 
dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer 
Group study. Br J Cancer, Vol. 99, N°2, pp.275-82 
Labianca R, & Merelli B. (2010). Screening and diagnosis for colorectal cancer: present and 
future. Tumori, Vol. 96, N°6, pp.889-901. 
Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, Francoual 
M, Renée N, Ferrero JM, Foa C, Namer M, Lacarelle B, & Milano G. (2006). 
Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer 
Res, Vol. 12, N°18, pp.5496-502. 
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, 
Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, & 
Penault-Llorca F. (2009). Analysis of PTEN, BRAF, and EGFR status in determining 
benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin 
Oncol, Vol. 27, N°35, pp.5924-30. 
Laurent-Puig P, Lievre A,& Blons H. (2009). Mutations and response to epidermal growth 
factor receptor inhibitors. Clin Cancer Res, Vol. 15, N°4, pp.1133-9. 
Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, 
& Robert J. (2007). Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene 
polymorphisms in colorectal cancer patients: relationships with treatment outcome. 
Pharmacogenomics, Vol. 8, N°12, pp.1693-703. 
Lenz HJ. (2004). Pharmacogenomics and colorectal cancer. Ann Oncol, Vol. 15, N°S4:iv, 
pp.173-7 
Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, 
Ducreux M, Rougier P, Penault-Llorca F, & Laurent-Puig P. (2006). KRAS mutation 
status is predictive of response to cetuximab therapy in colorectal cancer. Cancer 
Res, Vol. 66, N°8, pp.3992-5. 
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, 
Hayes DF, & Bast RC. (2006). ASCO 2006 update of recommendations for the use of 
tumor markers in gastrointestinal cancer. J Clin Oncol, Vol. 24, N°33, pp.5313-27.  
Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, Ruan ZX, Gao YT, & Zheng W. (2005). 
Association of genetic polymorphisms in the VEGF gene with breast cancer 
survival. Cancer Res, Vol. 65, N°12, pp.5015-9. 
Lu JF, Bruno R, Eppler S, Novotny W, Lum B, & Gaudreault J. (2008). Clinical 
pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother 
Pharmacol, Vol. 62, N°5, pp.779-86 
Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, & Lenz HJ. (2009). Thymidylate synthase 
gene variations: predictive and prognostic markers. Mol Cancer Ther, Vol. 8, N°5, 
pp.1000-7. 
Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, & Baiget M. (2004). UGT1A1 
gene variations and irinotecan treatment in patients with metastatic colorectal 
cancer. Br J Cancer, Vol. 91, N°4, pp. 678-82. 
Meckley LM, Neumann PJ. (2010) Personalized medicine: factors influencing 
reimbursement. Health Policy, Vol.94, N°2, pp.91-100. 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
274 
Mercier C, & Ciccolini J. (2006). Profiling dihydropyrimidine dehydrogenase deficiency in 
patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin 
Colorectal Cancer, Vol. 6, N°4, pp. 288-96. 
Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C, Blesius A, Duluc M, 
Franceschini F, Giacometti S, Salas S, Milano G, Favre R, Seitz JF, & Ciccolini J. 
(2007a). Toxic death case in a patient undergoing gemcitabine-based chemotherapy 
in relation with cytidine deaminase downregulation. Pharmacogenet Genomics, Vol. 
17, N°10, pp.841-4. 
Mercier C, & Ciccolini J. (2007b). Severe or lethal toxicities upon capecitabine intake: is 
DPYD genetic polymorphism the ideal culprit? Trends Pharmacol.Sci, Vol. 28, N°12, 
pp. 597-8. 
Mercier C, Brunet C, Yang C, Dupuis C, Bagarry-Liegey D, Duflo S, Giovanni A, Zanaret M, 
Lacarelle B, Duffaud F, & Ciccolini J. (2009). Pharmacoeconomic study in head and 
neck cancer patients: Impact of prospective DPD deficiency screening with 5-
fluorouracil (5-FU) dose tailoring on toxicities-related costs. J Clin Oncol, Vol. 27, 
N°15s, (suppl; abstr 6515). 
Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S & Gamelin E. (2006). 
Clinical relevance of different dihydropyrimidine dehydrogenase gene single 
nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther, Vol. 5, 
N°11, pp. 2895-904. 
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, 
Gambacorta M, Siena S, & Bardelli A. (2005). Gene copy number for epidermal 
growth factor receptor (EGFR) and clinical response to antiEGFR treatment in 
colorectal cancer: a cohort study. Lancet Oncol, Vol. 6, N°5, pp. 279-86. 
Popat S, Matakidou A, & Houlston RS. (2004). Thymidylate synthase expression and 
prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol, 
Vol. 22, N°3, pp. 529-36. 
Pullmann R Jr, Abdelmohsen K, Lal A, Martindale JL, Ladner RD, & Gorospe M. (2006). 
Differential stability of thymidylate synthase 3'-untranslated region polymorphic 
variants regulated by AUF1. J Biol Chem, Vol. 281, N°33, pp. 23456-63. 
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, 
Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini 
G, Silva R, Mattioli R, Floriani I, & Magnani M. (2007). Pharmacogenetic profiling 
in patients with advanced colorectal cancer treated with first-line FOLFOX-4 
chemotherapy. J Clin Oncol, Vol. 25, N°10, pp. 1247-54. 
Salgado J, Zabalegui N, Gil C, Monreal I, Rodríguez J, & García-Foncillas J. (2007). 
Polymorphisms in the thymidylate synthase and dihydropyrimidine 
dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in 
colorectal cancer. Oncol Rep, Vol. 17, N°2, pp. 325-8. 
Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone 
C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, & Siena S. (2007). 
Epidermal growth factor receptor gene copy number and clinical outcome of 
metastatic colorectal cancer treated with panitumumab. J Clin Oncol, Vol. 25, N°22, 
pp. 3238-45. 
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock 
B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, 
www.intechopen.com
Pharmacogenetics and Pharmacogenomics  
of Colorectal Cancer: Moving Towards Personalized Medicine 
 
275 
Miller KD; & ECOG 2100. (2008). Association of vascular endothelial growth factor 
and vascular endothelial growth factor receptor-2 genetic polymorphisms with 
outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in 
advanced breast cancer: ECOG 2100. J Clin Oncol, Vol. 26, N°28, pp. 4672-8. 
Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J et al. (2008). Role of genetic 
and nongenetic factors for fluorouracil treatment-related severe toxicity: a 
prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol, 
Vol. 26, N°13, pp. 2131-8. 
Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, & Clarke SJ. (2008). 
Thymidylate synthase and methylenetetrahydrofolate reductase gene 
polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. 
Clin Cancer Res, Vol. 14, N°3, pp. 817-25. 
Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph 
D, Diasio RB, & Lacopetta B. (2008). Prognostic significance of thymidylate 
synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase 
protein expression in colorectal cancer patients treated with or without 5-
fluorouracil-based chemotherapy. Ann Oncol, Vol. 19, N°5, pp. 915-9 
Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, & Lenz HJ. (2001). A 
polymorphism of the XRCC1 gene predicts for response to platinum based 
treatment in advanced colorectal cancer. Anticancer Res, Vol. 21, N°4B, pp. 3075-9. 
Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, & Lenz HJ. (2002). 
Association between glutathione S-transferase P1, T1, and M1 genetic 
polymorphism and survival of patients with metastatic colorectal cancer. J Natl 
Cancer Inst, Vol. 94, N°12, pp. 936-42. 
Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, & Lenz HJ. (2004). A 
multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 
5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J 
Cancer, Vol. 91, N°2, pp. 344-54. 
Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, & Choi S. (2006). Which gene is a dominant 
predictor of response during FOLFOX chemotherapy for the treatment of 
metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol, Vol. 13, 
N°11, pp. 1379-85.  
Sun XF, Ahmadi A, Arbman G, Wallin A, Asklid D, & Zhang H. (2005). Polymorphisms in 
sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal 
cancer risk and patients' survival. World J Gastroenterol, Vol. 11, N°43, pp. 6875-9 
Suttle B, Ball HA, Molimard M, Rajagopalan D, Swann S, Amado R, & Pandite L. (2010). 
Relationship between exposure to pazopanib and efficacy in patients with 
advanced renal cell carcinoma. J Clin Oncol Vol. 28, N°15s (suppl; abstr 3048).  
Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, 
Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, 
Bonura S, Boccalon M, Biason P, & Frustaci S. (2006). The role of UGT1A1*28 
polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in 
patients with metastatic colorectal cancer. J Clin Oncol, Vol. 24, N°19, pp. 3061-8. 
Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z, & Sugihara K. (1999). Relationship 
between intratumoral dihydropyrimidine dehydrogenase activity and gene 
expression in human colorectal cancer. Clin Cancer Res, Vol. 5, N°10, pp. 2836-9. 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
276 
Vallböhmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis 
AM, Sherrod AE, Danenberg KD, & Lenz HJ. (2006). Molecular determinants of 
irinotecan efficacy. Int J Cancer, Vol. 119, N°10, pp. 2435-42. 
Van Kuilenburg AB. (2004). Dihydropyrimidine dehydrogenase and the efficacy and toxicity 
of 5-fluorouracil. Eur J Cancer, Vol. 40, N°7, pp. 939-50. 
Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, & Pérez Ruixo JJ. (2010). 
Pharmacokinetic and pharmacodynamic perspectives on the clinical drug 
development of panitumumab. Clin Pharmacokinet, Vol. 49, N°11, pp.729-40 
Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, 
Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, 
Duffaud F, Seitz JF, Zanaret M, Lacarelle B, & Mercier C. (2011). DPD-based 
adaptive dosing of 5-FU in patients with head and neck cancer: impact on 
treatment efficacy and toxicity. Cancer Chemother Pharmacol, Vol. 67, N°1, pp. 49-56. 
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, 
Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, & Lenz HJ. (2007). FCGR2A 
and FCGR3A polymorphisms associated with clinical outcome of epidermal 
growth factor receptor expressing metastatic colorectal cancer patients treated with 
single-agent cetuximab. J Clin Oncol, Vol. 25, N°24, pp. 3712-8. 
Zhang X, Li L, Fourie J, Davie JR, Guarcello V, & Diasio RB. (2006). The role of Sp1 and Sp3 
in the constitutive DPYD gene expression. Biochim Biophys Acta, Vol. 1759, N°5, pp. 
247-56. 
Zintzaras E, Ziogas DC, Kitsios GD, Papathanasiou AA, Lau J, & Raman G. (2009). MTHFR 
gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-
analysis. Pharmacogenomics, Vol. 10, N°8, pp. 1285-94. 
www.intechopen.com
Colorectal Cancer - From Prevention to Patient Care
Edited by Dr. Rajunor Ettarh
ISBN 978-953-51-0028-7
Hard cover, 538 pages
Publisher InTech
Published online 17, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The projections for future growth in the number of new patients with colorectal cancer in most parts of the
world remain unfavorable. When we consider the substantial morbidity and mortality that accompanies the
disease, the acute need for improvements and better solutions in patient care becomes evident. This volume,
organized in five sections, represents a synopsis of the significant efforts from scientists, clinicians and
investigators towards finding improvements in different patient care aspects including nutrition, diagnostic
approaches, treatment strategies with the addition of some novel therapeutic approaches, and prevention. For
scientists involved in investigations that explore fundamental cellular events in colorectal cancer, this volume
provides a framework for translational integration of cell biological and clinical information. Clinicians as well as
other healthcare professionals involved in patient management for colorectal cancer will find this volume
useful.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Joseph Ciccolini, Fréderic Fina, L’Houcine Ouafik and Bruno Lacarelle (2012). Pharmacogenetics and
Pharmacogenomics of Colorectal Cancer: Moving Towards Personalized Medicine, Colorectal Cancer - From
Prevention to Patient Care, Dr. Rajunor Ettarh (Ed.), ISBN: 978-953-51-0028-7, InTech, Available from:
http://www.intechopen.com/books/colorectal-cancer-from-prevention-to-patient-care/pharmacogenetics-
pharmacogenomics-of-colorectal-cancer-moving-towards-personalized-medicine
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
